Don't know about the other antibodies but I'm pretty sure we've seen studies showing some fluctuating test results for the SARS-COV-2 antibodies including some decay over time. Given the duration of study an asymptomatic infection might also not be completely unlikely in a small subset of participants. So I would naively think "similar" levels is the best one could expect.
Best case scenario is that ME CFS LLPCs have more CD38 and are good targets that would explain why IGG drop between non responders and responders max difference was like 10-15%.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.